Screener
Theravance Biopharma TBPH Income Tax
Income Tax at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest expense (non-cash) | — | (643) |
| Interest and other income, net | 3,013 | 939 |
| Loss before income taxes | (6,470) | (14,138) |
| Provision for income tax benefit | 1,537 | 559 |
| Net loss | (4,933) | (13,579) |
| Net unrealized loss on available-for-sale investments | (123) | (7) |
| Total comprehensive loss | $(5,056) | $(13,586) |
| Net loss per share: |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's income tax?
- Theravance Biopharma (TBPH) reported income tax of -$1.54M in Q1 2026.
- How has Theravance Biopharma's income tax changed year-over-year?
- Theravance Biopharma's income tax decreased by 175.0% year-over-year, from -$559K to -$1.54M.
- What is the long-term trend for Theravance Biopharma's income tax?
- Over 3 years (2021 to 2025), Theravance Biopharma's income tax has grown at a 436.8% compound annual growth rate (CAGR), from -$151K to $23.35M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Theravance Biopharma's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude